Huberman Lab Recap: Paul Stamets on Mushrooms, Immunity, Psilocybin Research and the Mycelium Network
Takeaways and a timestamp guide from the Nov 16, 2026 Huberman Lab episode with mycologist Paul Stamets on medicinal mushrooms, immune research, psilocybin studies and risks, fungal networks and cleanup, and his push-up habit.
By the GNOUP team Β· Β· 11 min read
The newest full guest episode of the Huberman Lab podcast on Andrew Huberman's official YouTube channel, "Mushrooms for the Mind & Immune System | Paul Stamets," was published on November 16, 2026 and runs about 2 hours 29 minutes. Huberman's guest is Paul Stamets, a mycologist (someone who studies fungi) often described as a father of modern applied mycology. They cover how fungi evolved and why Stamets sees them as "miniature pharmaceutical factories," his research on mushroom extracts and the immune system, the state of psilocybin research along with its legal status and risks, non-psychedelic mushrooms studied for the brain and body, fungal networks that pass electrical signals, using fungi to clean up pollution, and the daily push-ups Stamets credits for his energy at 71.
This is an independent summary written by GNOUP. It is not affiliated with, sponsored by or endorsed by the Huberman Lab, Andrew Huberman, Paul Stamets or his companies. The views and claims described below belong to the speakers, not to GNOUP. This is general information only and is not medical advice. Talk with a doctor before starting any supplement, especially if you are pregnant, take medication or have a health condition, and do not use any mushroom product in place of vaccines or medical treatment. Psilocybin is illegal under US federal law, and nothing here encourages using it. Never eat a wild mushroom unless an expert has identified it: some deadly species look like edible ones. GNOUP has no connection to the sponsors, products or paid offers mentioned in the episode and does not promote them.
Note for families: this is an adult conversation. A large part of it is about psilocybin ("magic mushrooms") and other psychedelics, including how people use them. It may not suit younger viewers.
Key health tips and takeaways
These are the speakers' own views, experiences and habits, not instructions from GNOUP.
- Never forage blind. Stamets warned that some of the deadliest mushrooms in the world taste good, "but it's your last meal." Huberman called that the best argument he had heard for getting properly educated before picking and eating any wild mushroom. Stamets added that in Germany, pharmacists are trained to identify mushrooms for the public.
- Know who is talking. Stamets founded the company Fungi Perfecti and its Host Defense supplement line, and said he created the business to fund research he could not get grants for. Huberman said at the start that he has no financial relationship with the company. Stamets described the supplements he takes himself but said he "cannot make medical recommendations," and urged people to follow the science. GNOUP does not repeat product amounts or regimens here.
- Look at the research, including the bad news. Stamets pointed listeners to a reference site his team curates, mushroomreferences.com, which he said collects more than a thousand peer-reviewed papers on mushrooms, including reports of side effects. As one example, he said some people get an allergic skin reaction just from touching shiitake mushrooms.
- Fresh mushrooms spoil fast, and where they come from matters. He said most mushrooms rot within days because the fruiting body has a weak immune system, while the underground mycelium (the root-like network) does the defending. He said he is concerned about pollution in some imported mushroom products, based on his own testing.
- Brain and endurance mushrooms are slow, not instant. Asked about cordyceps, lion's mane and reishi, Stamets said any benefits people hope for take time to show up because cells take time to change, unlike coffee. He called a cordyceps study of about 73 people, who took it for two to three weeks before testing, the most believable evidence he knows of for better oxygen uptake and performance, and said reishi may help sleep quality. He said cordyceps research is muddled because several different fungi have been sold and studied under that name.
- Psilocybin is not a party drug. Both speakers stressed that psilocybin remains illegal to possess or sell under US federal law, with only some cities and states easing enforcement. Huberman said people with a personal or family history of psychosis or bipolar disorder face higher risk and need great caution, and Stamets agreed they need to be screened. Stamets called it "serious medicine" and said "we need to have adults in the room," including preparation, therapy and follow-up support.
- Not for kids. Huberman said he knows of no good data supporting psilocybin use for anyone under 18 and that the developing brain is already very plastic. Stamets agreed psychedelics are "not for everyone" and called for more studies.
- Therapy is the part nobody has standardized. Huberman said the goal is "directed plasticity," meaning the brain change has to be steered toward healing, and that what should happen in a therapy session is less well defined than dose or strain. Stamets said he twice turned down older father figures who asked him to guide them, because there would be no ongoing therapeutic support afterward.
- Be careful with antifungal drugs, and ask a specialist. Stamets said your skin carries its own community of fungi and microbes that helps protect you, and that he worries about disrupting it. He said he cannot speak with authority on fungi in the gut and suggested consulting dermatology experts and doctors. (Antifungal medicines are often necessary; follow your doctor's advice.)
- His one "most actionable" habit: push-ups. Stamets said he did 95 push-ups the morning of the interview, has done them since he was about 10, and keeps them going partly because his older brother died of cardiac arrest. He said he stops short of locking his elbows to protect his joints, and that he plans to add deep squats. He said he is 71, takes no prescription drugs and does not feel cognitive decline, which he attributes in part to mushrooms, calling himself "an N of one."
- Stay curious and humble. He described keeping a "question authority" bumper sticker, with "with respect and humor" added underneath, and urged listeners to ask why before criticizing others. He said "creativity breeds happiness."
Newsworthy insights
These are claims, opinions and interpretations from the episode. GNOUP has not checked them, and none are medical advice.
- Small studies on mushroom extracts and COVID-19. Stamets said his team and university collaborators ran privately funded early-stage trials of a blend of two of his company's mycelium products, made from turkey tail and agarikon, in about 140 people across two studies. He said results published in BMC Immunology showed fewer vaccine side effects than placebo and, when blood was retested six months later, higher antibody levels. In a second, smaller study of about 50 people who were already sick, he said symptoms eased days sooner than with placebo. He described these as phase 1 studies, mainly to test safety, and said the mechanism is still debated. These are early results involving his own products, not proof that any supplement prevents or treats COVID-19.
- A biodefense backstory. He said that after 9/11, a US biodefense screening program tested hundreds of his mushroom extracts, and that agarikon extracts stood out against pox and flu viruses in lab tests. He said a 20-year-old agarikon extract kept on a shelf later showed activity against the COVID virus in the lab, and that he recently received notice of a $2.6 million grant to search 130 agarikon strains for especially potent ones.
- Agarikon's genome. He said agarikon, a long-lived mushroom of old-growth forests that he said is on Europe's endangered "red list," has now had its full genome sequenced for the first time, published in the journal G3.
- Honeybee viruses. Stamets said a study he co-authored with Washington State University and USDA scientists found that mushroom extracts added to sugar water cut deformed wing virus levels in honeybees sharply within days, which he called important for crop pollination.
- "COVID's not the last pandemic." He warned about H5N1 bird flu spreading to many mammal species and about engineered threats, and argued that protecting biodiversity is protecting "biosecurity." He also said regulators' demand to characterize every compound in a complex natural product is a barrier, and that Europe's novel-food rules restrict the sale of mycelium products.
- Psilocybin by the numbers, as he cited them. Stamets said he saw 306 psilocybin clinical trials listed on clinicaltrials.gov that morning. He cited Johns Hopkins work led by the late Roland Griffiths in which, he recalled, about 70% of participants rated a high-dose session among the most positive experiences of their lives and about 30% found it difficult, without lasting harm reported. He said trials of a company's psilocybin treatment showed roughly 40 to 45% of people with hard-to-treat depression improving. He also argued, controversially, that psilocybin could prevent crime and addiction. Huberman said he hopes at least one psychedelic medicine reaches FDA approval, crediting a bipartisan push, and both said legal access should come with regulation and therapy.
- A large self-reported microdosing study. Stamets said a citizen-science app study he worked on enrolled up to about 25,000 people and reported improvements in mood, depression and anxiety, while acknowledging critics' point that expectation and placebo effects could explain much of it. He said a finger-tapping test, meant to sidestep expectation, showed faster tapping after 30 days in people using his "Stamets Stack" combination than in non-users. These are observational, self-reported results, not clinical trials.
- Natural forms vs. the pure drug. He said a small interview study of four people who had tried both pure psilocybin and the mushroom form found they all preferred the mushroom, describing a gentler, longer comedown.
- Fungi that "talk." He said mycelium networks carry dozens of distinct electrical signal patterns, and floated a speculative idea about shoes and clothing that could link people to these networks. He also connected NASA's reported discovery of the amino acid tryptophan in samples from asteroid Bennu to his personal belief that we live in a "tryptamine universe," while saying "let's be serious scientists. Where's the proof?"
- Cleanup: what works and what doesn't. Stamets said oyster mushroom mycelium has broken down diesel, gasoline and heavy ship oil in published tests, and that mycelium can filter E. coli from farm runoff. But he said, after spending millions on it, that fungi have been impractical for breaking down dioxins, PCBs and plastics outside the lab, because the mycelium eats easier food first. He suggested mushroom farms could become local cleanup supply centers.
- The push-up study. He cited a Harvard study on men who can do 40 push-ups and heart risk, saying "fact check me." He recalled a very large risk reduction; check the published study for the actual findings and who was studied.
Watch the episode
Mushrooms for the Mind & Immune System | Paul Stamets on YouTube (Andrew Huberman's official Huberman Lab channel, published November 16, 2026)
The Huberman Lab website also has show notes for the episode: episode page.
Episode guide
Chapter times are taken from the episode's official timestamp list. We left out the sponsor-message and closing sections. Select a time to jump to that point on YouTube.
- 0:00: Introducing Paul Stamets
- 3:25: Fungal evolution, complexity and "natural intelligence"
- 10:02: Where fungi live, mycelium and the immune system
- 17:43: His journey into mycology and his brother
- 21:14: Primates eating fungi, poisonous mushrooms, nutrition and fetal health
- 25:14: Medicinal mushrooms and antiviral research
- 30:26: The COVID pandemic, turkey tail, agarikon and vaccine studies
- 40:33: The immune system, vaccines and medicine, and the entourage effect
- 47:47: Pharmaceuticals and the natural world
- 53:28: Mushroom supplements and colds, his company and research
- 1:01:28: Skeptics, future pandemics, H5N1 and why biodiversity matters
- 1:11:39: Psilocybin and depression research
- 1:16:51: Psilocybin legality, people at higher risk, and reported benefits
- 1:21:41: Psychedelic therapy, neuroplasticity and therapeutic support
- 1:27:36: Psychedelics and legalization
- 1:36:12: Kids and psilocybin; the pharmaceutical version vs. the mushroom
- 1:42:11: Microdosing definitions and sensory perception
- 1:48:14: The microdosing study, mood, anxiety and the finger-tapping test
- 1:54:10: Cordyceps, lion's mane and reishi
- 1:59:55: Electrical signaling in mycelium networks, asteroid Bennu and tryptamines
- 2:09:48: Fungi on the skin and in the gut, and antifungal medicines
- 2:13:28: Mycoremediation: fungi and environmental pollutants
- 2:19:27: Push-ups, longevity, creativity and happiness
About this summary
This recap was prepared from the episode's official description and timestamps, the Huberman Lab website's episode listing and YouTube's automatic transcript of the full episode. Automatic transcripts can contain errors, and names and numbers may differ from the audio. For the exact words and context, watch the video. We deliberately left out dose amounts, supplement regimens and product recommendations discussed in the episode. This article is general information, not medical advice, and is not a substitute for guidance from a qualified healthcare professional.